97211 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
Anti-MUC16 antibodies and uses thereof
#302Humanized anti-MUC1* antibodies
#303Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof
#304Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
#305Anti-MCAM antibodies and associated methods of use
#306Oncolytic adenoviruses coding for bi-specific antibodies
#307PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES
#308Methods and compositions related to single chain antibody fragments that bind to tumor-associated glycoprotein 72 (TAG-72)
#309Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
#310Bispecific antibody capable of being combined with immune cells to enhance tumor killing capability, and preparation method therefor and application thereof
#311TARGETING CONSTRUCTS FOR DELIVERY OF PAYLOADS
#312Methods of increasing delivery of anti-cancer agents to targets
#313Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
#314Colon and pancreas cancer peptidomimetics
#315Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
#316Monoclonal antibodies, compositions and methods for detecting mucin-like protein (MLP) as a biomarker for ovarian and pancreatic cancer
#317Tn-MUC4 binding polypeptides and uses thereof
#318Antibodies that specifically bind to TIM3
#319Antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes
#320Humanized anti-Tn-MUC1 antibodies and their conjugates
#321Immunoconjugates with an intracellularly-cleavable linkage
#322Stable compositions of high-concentration allotype-selected antibodies for small-volume administration
#323Cysteine engineered antibodies and conjugates
#324T-cell redirecting bispecific antibodies for treatment of disease
#325Immunoconjugates with an intracellularly-cleavable linkage
#326Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
#327Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said
#328Human soluble CD146, preparation and uses thereof
#329Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (TAG-72)
#330MUC1* ANTIBODIES
#331Anti-MUC1 antibody or antigen-binding fragment thereof and uses thereof
#332Antibody to mucin 4 (MUC4) glycopeptide and uses thereof
#333Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
#334METHODS FOR INCREASING THE DIVERSITY OF MONOCLONAL ANTIBODIES PRODUCED AGAINST AN ANTIGEN
#335Anti-MCAM antibodies and associated methods of use
#336CHIMERIC ANTIGEN RECEPTORS RECOGNIZING CANCER-SPECIFIC TN GLYCOPEPTIDE VARIANTS
#337Anti-Pancreatic Cancer Antibodies
#338IgE antibodies for the inhibition of tumor metastasis
#339Use of Anti-MCAM Antibodies for Treatment or Prophylaxis of Giant Cell Arteritis, Polymyalgia Rheumatica or Takayasus Arteritis
#340Dock-and-Lock (DNL) Complexes for Therapeutic and Diagnostic Use
#341Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells
#342Xenoantigen-displaying anti-cancer vaccines and method of making
#343Anti-MCAM antibodies and associated methods of use
#344Immunoconjugates with an intracellularly-cleavable linkage
#345T-cell redirecting bispecific antibodies for treatment of disease
#346Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#347Anti-MCAM antibodies and associated methods of use
#348Antibodies and immunoconjugates
#349COMBINATION TREATMENT FOR MULTIPLE SCLEROSIS
#350Method of targeting glycoproteins to treat cancer
#351CA6 antigen-specific cytotoxic conjugate and methods of using the same
#352ANTIBODIES REACTIVE WITH AN EPITOPE LOCATED IN THE N-TERMINAL REGION OF MUC5AC COMPRISING CYSTEINE-RICH SUBDOMAIN 2 (CYS2)
#353Use of Anti-MUC1 Maytansinoid Immunoconjugate Antibody for the Treatment of Solid Tumors
#354Multimeric Complexes with Improved in Vivo Stability, Pharmacokinetics and Efficacy
#355Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
#356TUMOR SPECIFIC ANTIBODIES AND USES THEREFOR
#357Pharmaceutical kit and methods for cancer treatment via intracavity delivery and for preparing metal nanoparticle-antibody fragment conjugate
#358GLYCAN-INTERACTING COMPOUNDS
#359METHODS FOR TREATMENT OF OVARIAN CANCER
#360Peptidomimetic compounds and antibody-drug conjugates thereof
#361Antibody-SN-38 immunoconjugates with a CL2A linker
#362COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
#363Antibody-SN-38 immunoconjugates with a CL2A linker
#364DELIVERY SYSTEM FOR CYTOTOXIC DRUGS BY BISPECIFIC ANTIBODY PRETARGETING
#365Immunoconjugates with an intracellularly-cleavable linkage
#366Human monoclonal antibodies specific for glypican-3 and use thereof
#367Antibodies to endoplasmin and their use
#368Monoclonal antibody and derivatives
#369Compositions and methods for stabilizing protein-containing formulations
#370T-cell redirecting bispecific antibodies for treatment of disease
#371Methods and compositions related to single chain antibody fragments that bind to tumor-associated glycoprotein 72 (TAG-72)
#372Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies
#373T-Cell Redirecting Bispecific Antibodies for Treatment of Disease
#374Antibodies to MUC16 and methods of use thereof
#375Anti-mucin 1 binding agents and uses thereof
#376Glycan-interacting compounds
#377Cysteine engineered antibodies and conjugates
#378Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
#379Immunoconjugates with an intracellularly-cleavable linkage
#380Expression process
#381Detection of early-stage pancreatic adenocarcinoma
#382Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#383Use of human cells of myeloid leukemia origin for expression of antibodies
#384TUMOR SPECIFIC ANTIBODIES AND USES THEREFOR
#385Human monoclonal antibodies specific for glypican-3 and use thereof
#386Colon and pancreas cancer peptidomimetics
#387Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)
#388Antibody-SN-38 immunoconjugates with a CL2A linker
#389PROCESS FOR PREPARING STABLE ANTIBODY MAYTANSINOID CONJUGATES
#390Stem cell enhancing therapeutics
#391Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
#392Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
#393Method for stimulating or enhancing proliferation of cells by activating the mucin 1 (MUC1) receptor
#394Immunoconjugates with an intracellularly-cleavable linkage
#395Immunoconjugates with an intracellularly-cleavable linkage
#396Immunoconjugates with an intracellularly-cleavable linkage
#397Anti-mucin antibodies for early detection and treatment of pancreatic cancer
#398Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
#399Antibodies that specifically bind to TIM3
#400Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies
#401Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
#402Aberrant cell-restricted immunoglobulins provided with a toxic moiety
#403Methods and compositions for generating bioactive assemblies of increased complexity and uses
#404Method for the production of an immunostimulating mucin (MUC1)
#405Recognition molecules for the treatment and detection of tumors
#406Anti-mucin antibodies for early detection and treatment of pancreatic cancer
#407IgE antibodies for the inhibition of tumor metastasis
#408Immunoconjugates with an intracellularly-cleavable linkage
#409Immuno imaging agent for use with antibody-drug conjugate therapy
#410Immuno imaging agent for use with antibody-drug conjugate therapy
#411Anti-MCAM antibodies and associated methods of use
#412Anti-mucin antibodies for early detection and treatment of pancreatic cancer
#413Compositions and methods for detection and treatment of cancer
#414Method for making pluripotent stem cells
#415Glycan-interacting compounds
#416Human monoclonal antibodies specific for glypican-3 and use thereof
#417Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
#418Antibodies to endoplasmin and their use
#419TUMOR SPECIFIC ANITBODIES AND USES THEREFOR
#420Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies
#421Pharmaceutical composition
#422Tumor specific antibodies and uses therefor
#423Therapeutic and diagnostic cloned MHC-unrestricted receptor specific for the MUC1 tumor associated antigen
#424Colon and pancreas cancer peptidomimetics
#425Compositions and methods for stabilizing protein-containing formulations
#426Fab-glycosylated antibodies
#427Antibodies to MUC16 and methods of use thereof
#428Methods and compositions for generating bioactive assemblies of increased complexity and uses
#429Method for early detection of cancer
#430MUC1 antibody
#431Antibody against mucin 1 (MUC1) protein and use of same
#432ANTI-MUC1 ANTIBODIES FOR CANCER DIAGNOSTICS
#433Cancer-related glycopeptide epitopes, antibodies and methods of use
#434Antibodies that specifically bind to TIM3
#435Methods for Diagnosing The Malignant Potential of Pancreatic Cystic Lesions
#436Ultrafiltration concentration of allotype selected antibodies for small-volume administration
#437Anti-podoplanin antibody, and pharmaceutical composition containing anti-podoplanin antibody
#438CA-125 Immune Complexes as Biomarkers of Ovarian Cancer
#439MUC1 based glycolipopeptide vaccine with adjuvant
#440Multivalent Immunoglobulin-Based Bioactive Assemblies
#441MULTISPECIFIC MODULAR ANTIBODY
#442Compositions and Methods of Use of Immunotoxins Comprising Ranpirnase (Rap) Show Potent Cytotoxic Activity
#443GalNAc-SPECIFIC BINDING MOLECULES AND USES THEREOF
#444Design and Construction of Novel Multivalent Antibodies
#445METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES AND METHODS OF MAKING SAID CONJUGATES
#446MUC1 based glycolipopeptide vaccine with adjuvant
#447Anti-MUC1 α/β antibodies
#448Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
#449Immuno-conjugates and methods for producing them
#450Immuno-conjugates and methods for producing them
#451Anti-mucin antibodies for early detection and treatment of pancreatic cancer
#452MUC1 antibodies
#453COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
#454Immunoconjugates with an intracellularly-cleavable linkage
#455Recombinant fusion protein and polynucleotide construct for immunotoxin production
#456Anti-MUC1 antibody
#457Antibodies to endoplasmin and their use
#458Recombinant anti-MUC1 antibodies
#459Cysteine engineered antibodies and conjugates
#460Immunoconjugates with an intracellularly-cleavable linkage
#461Human soluble CD146, preparation and uses thereof
#462Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
#463Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells
#464METHOD FOR OBTAINING AN EXCIPIENT-FREE ANTIBODY SOLUTION
#465Methods and compositions for generating bioactive assemblies of increased complexity and uses
#466Compositions and methods for the diagnosis and treatment of tumor
#467Detection of early-stage pancreatic adenocarcinoma
#468Tumor specific antibodies and uses therefor
#469Multivalent immunoglobulin-based bioactive assemblies
#470Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
#471CA6 antigen-specific cytotoxic conjugate and methods of using the same
#472Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
#473Carbohydrate specific cellular immunity inducing microorganisms and fractions thereof
#474Method for the production of an immunostimulating mucin (MUC1)
#475Antibodies that bind GalNAc1-3Gal, pharmaceutical compositions and methods of using same
#476Anti-Muc 17 antibody
#477Methods for increasing the diversity of monoclonal antibodies produced against an antigen
#478Microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates
#479Chimeric, human and humanized anti-CSAP monoclonal antibodies
#480Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancer
#481Immunoconjugates with an intracellularly-cleavable linkage
#482Altered antibodies
#483Methods for detecting and treating cancer
#484Anti-Tumor Antibodies
#485Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies
#486Use of human cells of myeloid leukaemia origin for expression of antibodies
#487GAINAC SPECIFIC BINDING MOLECULES AND USES THEREOF
#488PRODUCTION OF ANTI-SELF ANTIBODIES FROM ANTIBODY SEGMENT REPERTOIRES AND DISPLAYED ON PHAGE
#489Anti-pancreatic cancer antibodies
#490Process for the production of monoclonal antibodies
#491Multivalent immunoglobulin-based bioactive assemblies
#492MUC1 EXTRACELLULAR DOMAIN AND CANCER TREATMENT COMPOSITIONS AND METHODS DERIVED THEREFROM
#493COMPOSITIONS COMPRISING AN ANTI-CA125 ANTIBODY AND A CYTOTOXIC COMPOUND AND THEIR USE FOR THE TREATMENT OF CANCER
#494Methods and compositions for generating bioactive assemblies of increased complexity and uses
#495Liposome-mediated ligation
#496BIOLOGICAL MATERIALS AND USES THEREOF
#497CA6 antigen-specific cytotoxic conjugate and methods of using the same
#498THERAPEUTIC AND DIAGNOSTIC CLONED MHC-UNRESTRICTED RECEPTOR SPECIFIC FOR THE MUC1 TUMOR ASSOCIATED ANTIGEN
#499Glycolipopeptide antibodies
#500Compositions and methods for the diagnosis and treatment of tumor
#501CA125 gene and its use for diagnostic and therapeutic interventions
#502Humanized anti-tag-72 monoclonal antibodies
#503Fused Protein Composition
#504Anti-Muc1 Alpha/Beta Antibodies
#505Chimeric, human and humanized anti-CSAp monoclonal antibodies
#506Chimeric, human and humanized anti-CSAP monoclonal antibodies
#507Chimeric, human and humanized anti-CSAp monoclonal antibodies
#508Agents and use thereof
#509Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
#510Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
#511Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
#512Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
#513Chimeric, human and humanized anti-CSAP monoclonal antibodies
#514PRODUCTION OF ANTI-SELF ANTIBODIES FROM ANTIBODY SEGMENT REPERTOIRES AND DISPLAYED ON PHAGE
#515Peptides and antibodies to MUC 1 proteins
#516PRODUCTION OF ANTI-SELF ANTIBODIES FROM ANTIBODY SEGMENT REPERTOIRES AND DISPLAYED ON PHAGE
#517Multivalent immunoglobulin-based bioactive assemblies
#518Method for the production of an immunostimulating mucin (muc1)
#519Methods and compositions for generating bioactive assemblies of increased complexity and uses
#520Vaccines
#521CA6 antigen-specific cytotoxic conjugate and methods of using the same
#522Dimer of chimeric recombinant binding domain-functional group fusion formed via disulfide-bond-bridge and the processes for producing the same
#523Specific mucin expression as a marker for pancreatic cancer
#524Recognition molecules for the treatment and detection of tumors
#525Therapeutic and diagnostic cloned MHC-unrestricted receptor specific for the MUC1 tumor associated antigen
#526Use of antibodies against the MUC18 antigen
#527Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
#528Methods for stimulating or enhancing proliferation of non-tumorous cells expressing MUC1 receptors
#529Biological materials and uses thereof
#530Techniques and compositions for diagnosis and treatment of cancer (muci)
#531Method of treating tumors
#532Methods for increasing the diversity of monoclonal antibodies produced against an antigen
#533Therapeutic adjuvant
#534Methods for treating cancer using Porimin as a target
#535Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
#536Chimeric, human and humanized anti-CSAp monoclonal antibodies
#537CA6 antigen-specific cytotoxic conjugate and methods of using the same
#538MUC1 extracellular domain and cancer treatment compositions and methods derived therefrom
#539MUC1 extracellular domain and cancer treatment compositions and methods derived therefrom
#540Peptides and antibodies to muc 1 proteins